

TREATMENT OF PATIENTS EXPOSED TO NERVE AGENTS GB, VX, AND ORGANOPHOSPHOROUS PESTICIDES

1. **The Hazardous Materials Response** policy should be applied to all responses involving these agents.
2. The following treatment should be considered only when the patient manifests typical symptoms of exposure to these agents and the scene is suggestive of exposure.
3. Mass Casualty Incident: Early recognition that field patient treatment needs will exceed immediately available supplies should prompt an immediate call to the CCC to initiate the release of Chempacks.
4. Symptoms: **Table 4.2**

D	Defecation	M	Muscle weakness and paralysis
U	Urination	T	Tachycardia
M	Miosis	W	Weakness
B	Bronchorrhea	TH	Hypertension
E	Excitation	F	Fasciculations
L	Lacrimation		
S	Salivation or seizures		

TREATMENT USING THE MARK 1 KIT:

1. Mild to moderate symptoms:
 - I. Establish a patent airway and adequate ventilation.
 - II. Administer 1 MARK 1 dose of **atropine** followed by one dose of **pralidoxime chloride** (2-PAM)*
 - III. Supplement by administering **O₂**.
 - IV. If symptoms persist after 5-10 minutes, repeat injections.
 - V. If symptoms persist in additional 10 minutes, repeat injections a third time.

2. Severe symptoms (respiratory compromise, seizure, or coma):
 - I. Administer auto injector kit, atropine and 2-PAM x3 in rapid succession.
 - II. If symptoms persist after third set of injections then **DO NOT** administer any more antidotes.
 - III. Slowly administer 1-2 mg of **lorazepam (Ativan®)** IV/IO/IM. May be repeated in 3-5 minutes, up to a total dose of 4 mg[†]

TREATMENT USING PEDS ATROPEN FOR ADULTS OR CHILDREN:

1. Atropine
 - A. Infant (0-3 years, < 13 kg): 0.05-0.1 mg/kg IM/IV or 0.2-1 mg Peds Atropen or MDV[‡]
 - B. Child (3-10 years, 13-35 kg): 1-4 mg IM/IV Peds Atropen, MDV or MARK1[‡]
 - C. Adolescent to adult: 2-6 mg IM/ IV MDV or MARK1
 - D. Elderly/frail: 1-4 mg IM/IV Peds Atropen, MDV or MARK 1[‡]
2. Pralidoxime (2-PAM)
 - A. Infant (0-3 years, < 13 kg): 25-50 MG/KG IM/IV or 150-600 mg MDV[‡]
 - B. Child (3-10 years, 13-35 kg): Administer 25-50 mg/kg IM/IV (or 300-1200 mg MDV or in MARK 1[‡]
 - C. Adolescent to adult (> 10 years, >35 kg):
 - a. Mild to moderate symptoms: Administer 1-3 doses IM sequentially from the MARK 1 Kit (or 600-1800 mg IM/IV from MDV)
 - b. Severe symptoms: Administer 3 doses IM from the MARK 1 Kits (or 1800 mg IM/IV from MDV)
 - D. Elderly/frail: 10-25 mg/kg IM/IV MDV or 2 PAM in MARK 1[‡]

TREATMENT OF SEIZURES WITH CHEMPACK SUPPLIED VALIUM

- A. Infant (0-3 years, < 13 kg): 0.2-0.5 mg/kg IM/IV or (1.25 mg-5 mg) MDV
- B. Child (3-10 years, 13-35 kg): 0.2-0.5 mg/kg IM/IV or (2.5 mg-10 mg) MDV or autoinjector
- C. Adolescent to adult: 5-10 mg IM/IV MDV or autoinjector
- D. Elderly/frail: 1.25-10 mg IM/IV MDV or autoinjector

*Warning: Morphine, theophylline, aminophylline, or succinylcholine should be used with caution for patients treated with 2-PAM.

†If patient's needs exceed immediately available supplies of lorazepam, diazepam may be substituted, 10 mg IM or autoinjector.

‡If MDV not available, IV route not established and/or precise dosing impossible, consider administration of MARK1.